Pharmacology
[Preprint] Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19: An international collaborative meta-analysis of randomized trials
20 Sep, 2020 | 21:42h | UTC
Commentary on Twitter
This meta-analysis of 7,913 patients from 26 RCTs (16 unpublished) found no mortality benefit to #hydroxychloroquine or chloroquine in COVID19
Combined summary OR for all-cause mortality for HCQ 1.08, 95%CI 0.99-1.18
Confirms HCQ does not help, may harmhttps://t.co/4o9bXkOo5Q pic.twitter.com/QG1XMzN0da
— Ilan Schwartz MD PhD (@GermHunterMD) September 19, 2020
Who gets a COVID vaccine first? Access plans are taking shape
20 Sep, 2020 | 21:24h | UTCWho gets a COVID vaccine first? Access plans are taking shape – Nature
Related: WHO Guidance: Allocation and prioritization of COVID-19 vaccination
Commentary on Twitter
Advisory groups around the world are working out plans for who should get priority access to a #covid19 vaccine: https://t.co/9g67rFJUrT pic.twitter.com/BLhAcKiVCK
— Nature News & Comment (@NatureNews) September 18, 2020
[Abstract Only] Survival with Olaparib in metastatic castration-resistant prostate cancer
20 Sep, 2020 | 21:13h | UTC
Commentary on Twitter
The PROfound trial showed that olaparib prolonged imaging-based progression-free survival among patients whose tumors contained defects in the BRCA1, BRCA2, or ATM. With longer follow-up, the trial now shows that olaparib prolonged overall survival in these patients. #ESMO20
— NEJM (@NEJM) September 20, 2020
[Abstract Only] Avelumab maintenance therapy for advanced or metastatic urothelial carcinoma
20 Sep, 2020 | 21:11h | UTC
Commentary on Twitter
Maintenance avelumab plus best supportive care significantly prolonged overall survival, as compared with best supportive care alone, among patients with urothelial cancer who had disease that had not progressed with first-line chemotherapy. #ESMO20
— NEJM (@NEJM) September 18, 2020
Two pharma companies released their coronavirus vaccine blueprints in a bid to regain public trust
18 Sep, 2020 | 09:30h | UTC
Study: Longer-than-necessary duration of outpatient antibiotic therapy for common outpatient infections
18 Sep, 2020 | 09:21h | UTC
Commentary on Twitter
NEW #CID using large NDTI dataset,clinicians defaulted 10d courses for most conditions, regardless of guideline-recommendations. Median antibiotic course
duration was 10 days for all conditions except acute cystitis. #IDTwitter https://t.co/WTJBFEcRtk pic.twitter.com/TAx7twUoTo— Antibiotic Steward🆔 Bassam Ghanem (@ABsteward) September 16, 2020
Antimicrobial resistance: The next big pandemic?
18 Sep, 2020 | 09:19h | UTCAntimicrobial resistance: The next big pandemic? – Open Access Government
WHO Guidance: Allocation and prioritization of COVID-19 vaccination
17 Sep, 2020 | 09:42h | UTCCommentary: World Health Organization announces distribution plan for COVID-19 vaccine – ABD News
Related: An ethical framework for global vaccine allocation – Science
[Press release – not published yet] Eli Lilly reports first, promising results for an antibody against COVID-19
17 Sep, 2020 | 09:28h | UTCEli Lilly reports first, promising results for an antibody against COVID-19 – Science
Press release: Lilly announces proof of concept data for neutralizing antibody LY-CoV555 in the COVID-19 outpatient setting
[Abstract Only] Two-year, randomized, controlled trial of belimumab in lupus nephritis
17 Sep, 2020 | 09:20h | UTCTwo-Year, Randomized, Controlled Trial of Belimumab in Lupus Nephritis – New England Journal of Medicine (link to abstract – $ for full-text)
Lifelong aspirin for all in the secondary prevention of chronic coronary syndrome: Still sacrosanct or is reappraisal warranted?
17 Sep, 2020 | 09:19h | UTCLifelong Aspirin for All in the Secondary Prevention of Chronic Coronary Syndrome: Still Sacrosanct or is Reappraisal Warranted? – Circulation (free for a limited period)
Perspective: Up is down — pharmaceutical industry caution vs. federal acceleration of Covid-19 vaccine approval
16 Sep, 2020 | 09:06h | UTC
UK tests if COVID-19 vaccines might work better inhaled
16 Sep, 2020 | 08:56h | UTCUK tests if COVID-19 vaccines might work better inhaled – Associated Press
Coronavirus: Monoclonal antibodies to begin UK trial
16 Sep, 2020 | 08:53h | UTCCoronavirus: Monoclonal antibodies to begin UK trial – BBC
See also: Covid-19: RECOVERY trial will evaluate “antiviral antibody cocktail” – The BMJ
AHA Scientific Statement: Drug-induced arrhythmias
16 Sep, 2020 | 08:50h | UTCDrug-Induced Arrhythmias: A Scientific Statement From the American Heart Association – Circulation
Commentary: Drug Proarrhythmia
Top Things to Know: Drug-Induced Arrhythmias
News Release: Identifying, preventing and managing heart rhythm side effects of medicines
NIH launches two trials to test blood thinners in COVID-19 patients
15 Sep, 2020 | 08:56h | UTCNIH launches two trials to test blood thinners in COVID-19 patients – Reuters
Scientists relieved as coronavirus vaccine trial restarts — but question lack of transparency
15 Sep, 2020 | 08:53h | UTC
Perspective: Vaccine transparency
15 Sep, 2020 | 08:48h | UTCVaccine Transparency – Science Translational Medicine
Coronavirus: Who would get the vaccine first?
15 Sep, 2020 | 08:47h | UTCCoronavirus: Who would get the vaccine first? – BBC
[Abstract Only] Preliminary trial on the effectiveness of Curcuma longa extract for the treatment of knee osteoarthritis
15 Sep, 2020 | 08:38h | UTCCommentaries: Turmeric May Help Relieve Pain from Knee Osteoarthritis – NEJM Journal Watch
Largest global vaccine confidence survey reveals hesitancy hotspots
14 Sep, 2020 | 01:16h | UTCThe Lancet Infographics: How global perceptions of vaccines have changed
Commentary on Twitter
New research mapping global trends in vaccine confidence across 149 countries between 2015-19 & based on data from over 284,000 adults surveyed about their views on whether vaccines are important, safe and effective, reveals vaccine hesitancy hotspots https://t.co/cbgCLEFF0C
— The Lancet (@TheLancet) September 10, 2020
Updated meta-analysis: Drug treatments for Covid-19
14 Sep, 2020 | 01:04h | UTCDrug treatments for covid-19: living systematic review and network meta-analysis – The BMJ
Commentary on Twitter
Our first update of our living NMA on treatments for covid-19 is published today: https://t.co/xRiSBkuRyG#COVID19
— ReedSiemieniuk. (@RSiemieniuk) September 11, 2020
A COVID-19 vaccine may be only 50% effective. Is that good enough?
14 Sep, 2020 | 01:03h | UTCA COVID-19 Vaccine May Be Only 50% Effective. Is That Good Enough? – NPR
AstraZeneca resumes Covid-19 vaccine trials in the U.K.
14 Sep, 2020 | 01:01h | UTCAstraZeneca resumes Covid-19 vaccine trials in the U.K. – STAT
See also: The ethics of pausing a vaccine trial in the midst of a pandemic: a conversation with Ruth Faden – STAT AND University of Oxford resumes vaccine trial
[Abstract Only] Randomized trial: Valaciclovir to prevent vertical transmission of cytomegalovirus after maternal primary infection during pregnancy
14 Sep, 2020 | 00:58h | UTC